Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "QIAGEN"

6 News Found

Helix and QIAGEN to jointly develop and commercialize companion diagnostics for hereditary diseases
Diagnostic Center | January 06, 2023

Helix and QIAGEN to jointly develop and commercialize companion diagnostics for hereditary diseases

Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise


QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency
News | August 16, 2022

QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency

QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms


QIAGEN selects TCS for cloud transformation strategy
Digitisation | June 16, 2022

QIAGEN selects TCS for cloud transformation strategy

QIAGEN has started its cloud transformation journey with the firm belief that cloud computing can be a key enabler of future business growth


QIAGEN and GT Molecular collaborate to detect SARS-CoV-2 in wastewater
Drug Approval | August 11, 2021

QIAGEN and GT Molecular collaborate to detect SARS-CoV-2 in wastewater

Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases


QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
Drug Approval | August 10, 2021

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab


QIAGEN receives U.S. FDA emergency use authorization to analyze over 30 samples per hour
Digitisation | August 10, 2021

QIAGEN receives U.S. FDA emergency use authorization to analyze over 30 samples per hour

QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes